Arrowhead Research | ARWR - Ebit


Arrowhead Research reported $57.82M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Arrowhead Research USD 57.82M 223.36M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
Merck USD 7.56B 1.19B Sep/2025
Moderna USD -260M 557M Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025
Xencor USD -47.52M 24.69M Sep/2025